perphenazine has been researched along with Basal Ganglia Diseases in 27 studies
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perphenazine is a treatment option in postoperative nausea and vomiting (PONV) prophylaxis." | 3.80 | Extrapyramidal symptoms following administration of oral perphenazine 4 or 8 mg: an 11-year retrospective analysis. ( Henao, JP; Lichvar, AB; Orebaugh, SL; Peperzak, KA; Pippi, MA; Skledar, SJ; Williams, BA, 2014) |
| "An 8-year-old child was given perphenazine to prevent vomiting after surgery and developed an acute dystonic reaction; There were features of both tetany and tetanus without any of the classical features of extrapyramidal disturbance." | 3.65 | Tetany, tetanus or drug reaction? A case report. ( Smith, WD; Tobias, MA, 1976) |
| "Perphenazine-treated patients had a higher incidence of extrapyramidal symptom-related adverse events, mean increases (i." | 2.73 | Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. ( Carson, WH; Kane, JM; Marcus, RN; McQuade, RD; Meltzer, HY; Sanchez, R, 2007) |
| "Perphenazine level was not correlated with EPS; but benztropine, given only if required for serious EPS, was more likely to be used when perphenazine levels were elevated." | 2.67 | The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. ( Bowers, MB; Jatlow, PI; Kincare, P; Mazure, CM; Nelson, JC, 1990) |
| " Twenty normal subjects were tested four times in a double blind study in order to control the short- and long-term effects of a low dosage of perphenacine." | 2.64 | [Psychometric effects of perphenacine below the "neuroleptic threshold" (author's transl)]. ( Jacobi, P; Maxion, HH, 1975) |
| "Perphenazine enanthate did not cause inappetence, reduced appetite, or any of the previously mentioned side effects when used alone." | 1.31 | Evaluation of long-term sedation in cheetah (Acinonyx jubatus) with perphenazine enanthate and zuclopenthixol acetate. ( Huber, C; Slotta-Bachmayr, L; Walzer, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (59.26) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 5 (18.52) | 29.6817 |
| 2010's | 2 (7.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henao, JP | 1 |
| Peperzak, KA | 1 |
| Lichvar, AB | 1 |
| Orebaugh, SL | 1 |
| Skledar, SJ | 1 |
| Pippi, MA | 1 |
| Williams, BA | 1 |
| Kim, E | 1 |
| Correll, CU | 1 |
| Mao, L | 1 |
| Starr, HL | 1 |
| Alphs, L | 1 |
| Huber, C | 1 |
| Walzer, C | 1 |
| Slotta-Bachmayr, L | 1 |
| Baffoni, L | 1 |
| Pedrazzi, R | 1 |
| Neri, R | 1 |
| Marzaloni, M | 1 |
| Andersen, TH | 1 |
| Bech, P | 1 |
| Larsen, NE | 3 |
| Kane, JM | 1 |
| Meltzer, HY | 1 |
| Carson, WH | 1 |
| McQuade, RD | 1 |
| Marcus, RN | 1 |
| Sanchez, R | 1 |
| Hansen, LB | 2 |
| Vestergård, P | 1 |
| Gulmann, N | 1 |
| Peacock, L | 1 |
| Solgaard, T | 1 |
| Lublin, H | 1 |
| Gerlach, J | 1 |
| Coley, KC | 1 |
| Carter, CS | 1 |
| DaPos, SV | 1 |
| Maxwell, R | 1 |
| Wilson, JW | 1 |
| Branch, RA | 1 |
| Gil-ad, I | 1 |
| Shtaif, B | 1 |
| Shiloh, R | 1 |
| Weizman, A | 1 |
| Cavenar, JO | 1 |
| Braasch, ER | 1 |
| Sullivan, JL | 1 |
| Obukhov, GA | 1 |
| Van Praag, HM | 1 |
| Korf, J | 1 |
| Smith, WD | 1 |
| Tobias, MA | 1 |
| Swett, C | 1 |
| Jacobi, P | 1 |
| Maxion, HH | 1 |
| Gerken, A | 1 |
| Wetzel, H | 1 |
| Benkert, O | 1 |
| Mazure, CM | 1 |
| Nelson, JC | 1 |
| Jatlow, PI | 1 |
| Kincare, P | 1 |
| Bowers, MB | 1 |
| Beckers, W | 1 |
| Shintomi, K | 1 |
| Yamamura, M | 1 |
| Stern, P | 1 |
| Valjevac, K | 1 |
| Snyder, SH | 1 |
| Greenberg, D | 1 |
| Yamumura, HI | 1 |
| von Domarus, H | 1 |
| Rodová, A | 1 |
| Náhunek, K | 1 |
| Svestka, J | 1 |
| Villeneuve, A | 1 |
| Ramsden, PD | 1 |
| Froggatt, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia[NCT02918825] | 100 participants (Actual) | Interventional | 2016-09-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for perphenazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Antiparkinson drugs in paranoid schizophrenia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Haloperidol; Humans; Perphenazin | 1979 |
8 trials available for perphenazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazep | 2016 |
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Buspirone; Denmark; Drug Thera | 2005 |
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Drug Resista | 2007 |
Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Female; Flupenthixol; Humans; | 1996 |
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonist | 1999 |
[Psychometric effects of perphenacine below the "neuroleptic threshold" (author's transl)].
Topics: Adult; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Female; Humans; Male; Perphenazine; | 1975 |
The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Dose- | 1990 |
An attempt to classify neuroleptic drugs on the basis of short-term clinical comparative studies.
Topics: Basal Ganglia Diseases; Clinical Trials as Topic; Drug Evaluation; Humans; Perphenazine; Schizophren | 1974 |
18 other studies available for perphenazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Extrapyramidal symptoms following administration of oral perphenazine 4 or 8 mg: an 11-year retrospective analysis.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Surgical Procedures; Basal Ganglia Diseases; Dop | 2014 |
Evaluation of long-term sedation in cheetah (Acinonyx jubatus) with perphenazine enanthate and zuclopenthixol acetate.
Topics: Acinonyx; Akathisia, Drug-Induced; Animals; Animals, Zoo; Antipsychotic Agents; Basal Ganglia Diseas | 2001 |
An unexpected increase of troponin I after perphenazine depot injection.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Middle Aged; Perphenazine; Troponin I | 2004 |
Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Female; Humans; Male; Middle Aged; Perphenazine; Prolacti | 1981 |
Dose-response relationships of perphenazine in the treatment of acute psychoses.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Female; | 1982 |
Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Cell Cycle; Cell Survival; Clozapine; | 2001 |
[Prolonged action neuroleptics (review of the foreign literature)].
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Child; Chronic Diseas | 1975 |
Importance of dopamine metabolism for clinical effects and side effects of neuroleptics.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Dopamine; Dopamine Antago | 1976 |
Tetany, tetanus or drug reaction? A case report.
Topics: Antiemetics; Basal Ganglia Diseases; Child, Preschool; Diagnosis, Differential; Diazepam; Humans; Pe | 1976 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.
Topics: Acute Disease; Adult; Aged; Basal Ganglia Diseases; Female; Handwriting; Humans; Male; Middle Aged; | 1991 |
[Gilles de la Tourette's disease based on five own observations].
Topics: Adolescent; Adult; Basal Ganglia Diseases; Compulsive Behavior; Diazepam; Dibenzocycloheptenes; Echo | 1973 |
Letter: Effects of antiparkinsonian drugs on neuroleptic-induced extrapyramidal signs in monkeys.
Topics: Animals; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Glycolates; Haloperidol; Haplorh | 1973 |
The effect of phenothiazines on botulinus intoxication.
Topics: Animals; Antitoxins; Arachnida; Basal Ganglia Diseases; Botulinum Toxins; Botulism; Butyrophenones; | 1974 |
Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Binding, Competitive; Brain; Chlorpromazine; | 1974 |
[Extrapyramidal motor disorders in neuroleptic therapy (apparent recurring luxation of mandibular joints)].
Topics: Antiparkinson Agents; Basal Ganglia Diseases; Child; Female; Humans; Joint Dislocations; Perphenazin | 1973 |
The rabbit syndrome. A peculiar extrapyramidal reaction.
Topics: Aged; Anxiety; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Fatigue; Female; Humans; Male; M | 1972 |
Idiosyncratic responses to phenothiazines.
Topics: Basal Ganglia Diseases; Diazepam; Humans; Movement Disorders; Parasympatholytics; Perphenazine; Trop | 1972 |